A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf
.
Real-World Data on Thromboprophylaxis in Active Cancer Patients: Where Are We? Are We Getting There?
2020
Cancers
Cancer patients are at high risk for cancer-associated thrombosis (CAT). CAT is the second leading cause of death in these patients but it can be preventable with thromboprophylaxis. Patients and Methods: An observational, prospective, multicenter study aiming to record CAT management in clinical practice was conducted by the Hellenic Society of Medical Oncology (HeSMO). Results: A total of 426 active cancer patients (mean age 65.3 years, mean BMI: 26.1 kg/m2) who received thromboprophylaxis,
doi:10.3390/cancers12071907
pmid:32679747
pmcid:PMC7409213
fatcat:ep4hl4wo4bb7hgi5j6m3lq5ssa